CURRENT
ISSUE
1616

On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020.1

CLINICAL STUDY — Issuance of the EUA was based primarily on the results of an observer-blind trial in which 30,420 subjects ≥18 years old were randomized 1:1 to receive the Moderna vaccine or placebo at 0 and 4 weeks. Immunocompromised persons and those with a history of SARSCoV-2 infection were excluded. There were 11 cases of COVID-19 among subjects who...  Continue reading

More from Issue 1616
Previous Issue: 1615      January 11, 2021
Coming Soon
Twirla - A New Contraceptive Patch
Pitolisant (Wakix) for Narcolepsy
Osilodrostat (Isturisa) for Cushing's Disease
Avapritinib (Ayvakit) for GIST
Drugs for Parkinson's Disease
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
FROM
ISSUE
1616

Treatment of community-acquired pneumonia (CAP) is usually empiric, with selected antibiotic regimens directed against some of the most common causative pathogens. Recommended empiric regimens are listed in Table 2; recommended antibiotic dosages for treatment of CAP are listed in Tables 3 and 4. Joint guidelines for treatment of CAP by the American Thoracic Society and the Infectious Diseases Society of America ... Continue reading

 Tweets